SINGAPORE , Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will be presenting at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7 th, 2023 at the New York Athletic Club in New York City. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which CytoMed Therapeutics will be participating in one-on-one meetings with investors and analysts throughout the day.
CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf cell therapies. By the end of 2024, CytoMed expects to have human data from two programs and pre-clinical data for its most promising program.
CytoMed Therapeutics (NASDAQ: GDTC ) stock is rocketing higher on Tuesday despite a lack of news concerning the company this morning. Instead of a press release of filing sending the shares higher, heavy trading is behind today's movement.